Glen Tullman Launches Livongo Health On $10 Million Seed Investment

image 

Former Allscripts CEO Glen Tullman launched his consumer health startup Livongo Health at today’s TechCrunch Disrupt SF conference, held on Pier 48 in San Francisco. The startup is being backed by General Catalyst, who provided Tullman with a $10 million seed  investment to get his company off the ground. Details on the investment were not disclosed, however General Catalyst was able to place both its managing director Hemant Taneja and principal Niko Bonatsos on Livongo’s board of directors.

Livongo Health is building a technology-focused chronic disease management platform that it hopes will take some of the burden out of managing complex medical conditions. Its first efforts are focused on diabetes care. Tullman developed a strong interest in diabetes after his son was diagnosed. He now serves as the chancellor to the International Board of the Juvenile Diabetes Research Foundation.

Earlier this week, Livongo received FDA clearance for the first digital glucometer with a built-in two-way communications device. The glucometer, which looks more like a smartphone than a medical device, captures and stores patient glucose levels and then pushes the data to a secure cloud-based data exchange platform. The exchange is used to send the data to the patients care team and family members. The entire platform has been designed to support the needs of both the patient, and the health systems and payers responsible for their long term care. The device does more than simply read glucose levels, however. It has the capability to help improve disease management by alerting clinicians of dangerous glucose readings, and could help improve medication adherence by tracking when patients check their glucose levels, and alerting family members when more than a day goes by without a reading.

Tullman is bullish on the potential to monetize his digitally-connected diabetes management platform. He explains, “This is a $250 billion market in the US that affects one out of every ten people.” Eventually, he says, the company will expand its focus to target a broad range of costly chronic diseases.


Enjoy HIStalk Connect? Sign up for update alerts, or follow us at @HIStalkConnect.

↑ Back to top

Founding Sponsors

Platinum Sponsors